Certara UK Ltd. Researchers Discuss Findings in Pharmaceutics (Applications of the Cholesterol Metabolite, 4b-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework).

Researchers from Certara UK Ltd. have developed a physiologically based pharmacokinetic (PBPK) model to evaluate the use of 4b-hydroxycholesterol (4b-OHC) as a biomarker for hepatic CYP3A activity. The model successfully simulated plasma 4b-OHC levels in different populations and captured changes in levels due to CYP3A inducers like rifampicin. This study offers a quantitative modeling framework for assessing drug-drug interaction risks related to hepatic CYP3A induction. [Extracted from the article]